In CAA, the up-regulated NNT-AS1 can compete with miR-485 to bind to B-cell CLL/lymphoma 9 protein (BCL9), thereby increasing the expression of BCL9 and promoting the proliferation, migration, and invasion of CCA cells [22]. This evidence concerns the gene BCL9 and cholangiocarcinoma.